INCB019602 + metformin

INCB019602 + metformin is an experimental drug combination consisting of INCB019602, an investigational agent, and metformin, a well-established antidiabetic drug. INCB019602 is reported by Incyte Corporation to be a selective inhibitor of hematopoietic progenitor kinase 1 (HPK1), intended as a cancer immunotherapy; it is investigated mainly in oncology settings, often in combination with other agents such as immune checkpoint inhibitors. Metformin is a biguanide widely used for type 2 diabetes and is also being evaluated in various oncology and metabolic disease contexts due to possible antitumor metabolic effects. The combination is under clinical investigation and has not received regulatory approval for any indication.